MSA-2
Based on 34 publication(s) in Google Scholar
MSA-2, a potent and orally available non-nucleotide STING agonist, is bound to STING as a noncovalent dimer with nanomolar affinity. MSA-2 shows EC50s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 stimulates interferon-β secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models.
For research use only. We do not sell to patients.
- Purity: 99.81%
- CAS No.: 129425-81-6
- Formula: C14H14O5S
- Molecular Weight:294.32
-
Storage:
4°C, protect from light
* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
Publications Citing Use of MedChemExpress (MCE) MSA-2
More- Nature. 2023 Apr;616(7958):806-813. [Abstract]
- Cancer Cell. 2024 May 13;42(5):850-868.e9. [Abstract]
- J Hematol Oncol. 2022 Oct 8;15(1):142. [Abstract]
- Adv Mater. 2023 Mar;35(10):e2209910. [Abstract]
- Cancer Res. 2025 Apr 11. [Abstract]
- Mol Cell. 2023 May 4;83(9):1502-1518.e10. [Abstract]
- Nat Commun. 2026 Feb 9;17(1):1441. [Abstract]
- Nat Commun. 2025 Jul 1;16(1):5773. [Abstract]
- Cell Death Differ. 2024 Jan;31(1):78-89. [Abstract]
- Adv Sci (Weinh). 2024 Nov 19:e2407222. [Abstract]
- Mater Today Bio. 2024 Apr 16:26:101057. [Abstract]
- BMC Med. 2024 Mar 5;22(1):96. [Abstract]
- Free Radic Biol Med. 2026 Apr:247:71-94. [Abstract]
- ACS Appl Mater Interfaces. 2024 Oct 9;16(40):53474-53488. [Abstract]
- Free Radic Biol Med. 2023 Aug 20:205:262-274. [Abstract]
- Oncogene. 2026 Jun;45(23):2211-2224. [Abstract]
- Oncogene. 2026 Mar;45(9):809-822. [Abstract]
- J Med Chem. 2026 May 14;69(9):11044-11071. [Abstract]
- Sci Signal. 2026 Jun 23;19(943):eaef1474. [Abstract]
- Oncoimmunology. 2025 Dec;14(1):2534912. [Abstract]
- OncoImmunology. 2022 Feb 1;11(1):2030021. [Abstract]
- PLoS Pathog. 2026 Jan 13;22(1):e1013868. [Abstract]
- Int Immunopharmacol. 2025 Oct 10:167:115637. [Abstract]
- Int Immunopharmacol. 2025 Jan 2:147:113968. [Abstract]
- Cell Rep Methods. 2025 Jul 21;5(7):101106. [Abstract]
- Sci Rep. 2022 Oct 24;12(1):17827. [Abstract]
- Mol Divers. 2025 Dec 11. [Abstract]
- Bioorg Med Chem. 2026 Jan 16:135:118571. [Abstract]
- Cardiovasc Intervent Radiol. 2025 Oct 31. [Abstract]
- Chem Biodivers. 2024 Jul 12:e202401253. [Abstract]
- Biomed Res. 2026;47(3):89-101. [Abstract]
- Cell Insight. 2025 May 22;4(4):100255. [Abstract]
- University of Rhode Island
- University of Rhode Island. 2024.
-
Bio/Physico-chemical Assay
-
Cell Proliferation/Viability Assay
-
Cell Migration/Invasion Assay
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
Biological Activity
MSA-2 (PO: 60 mg/kg or SC: 50 mg/kg; single dose) that effectively inhibits tumor growth induced substantial elevations of IFN-β, interleukin-6 (IL-6), and TNF-α in tumor[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MC38 tumor-bearing C57BL6 mice[1]
-
Dosage:60 mg/kg
-
Administration:P.o. ; s.c (50 mg/kg); single dose
-
Result:PO or SC doses of MSA-2 that effectively inhibited tumor growth induced substantial elevations of IFN-β, interleukin-6 (IL-6), and TNF-α in tumor.
Chemical Information
-
CAS No. 129425-81-6
-
Appearance Solid
-
Molecular Weight 294.32
-
Formula C14H14O5S
-
Color Off-white to light yellow
-
SMILES
O=C(C1=CC(C(S1)=C2)=CC(OC)=C2OC)CCC(O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
Publications (34)
-
Journal Impact Factor
-
Most Recent
-
Nature
2023 Apr;616(7958):806-813. PMID: 36991128
MSA-2 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Apr;616(7958):806-813. [Abstract]
Athymic mice were inoculated with 1×105 WT or STING knockout H2087-LCC cells via the tail vein and treated with vehicle or MSA-2 (50 mg/kg; subcutaneous injection) once weekly for 4 weeks starting two weeks after inoculation. Lungs were harvested 6 weeks after inoculation and the number of DTEs were counted.
-
Cancer Cell
2024 May 13;42(5):850-868.e9. PMID: 38670091
MSA-2 purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 May 13;42(5):850-868.e9. [Abstract]
Cell viability assays of isogenic NTC, Trp53 KO, and Bak/Bax KO Eμ-Myc lymphoma cell lines treated with S63845 in combination with ADU-S100 (2-10 μg/mL), MSA-2 (12-34 μM), or diABZI for 24 h.
-
J Hematol Oncol
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors. [Abstract]2022 Oct 8;15(1):142. PMID: 36209176
MSA-2 purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2022 Oct 8;15(1):142. [Abstract]
FACS for DC maturation markers. Immature BMDCs were cultured with MSA-2 (0.3-20 μg/mL) for one day and collected for flow cytometry. MSA-2 increased CD80, CD86, H-2Kd (MHC-I), I-A/I-E (MHC-II) dose-dependent.
MSA-2 purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2022 Oct 8;15(1):142. [Abstract]
The antitumor activity of MSA-2 plus YM101 in murine models. MSA-2 was administrated orally with a single dose of 50 mg/kg. Mice received equivalent mole Ab treatment on alternate days three times.
-
Adv Mater
Acid-Ionizable Iron Nanoadjuvant Augments STING Activation for Personalized Vaccination Immunotherapy of Cancer. [Abstract]2023 Mar;35(10):e2209910. PMID: 36576344 -
Cancer Res
Dissecting FAP+ Cell Diversity in Pancreatic Cancer Uncovers an Interferon-Response Subtype of Cancer-Associated Fibroblasts with Tumor-Restraining Properties. [Abstract]2025 Apr 11. PMID: 40215177
MSA-2 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Apr 11. [Abstract]
MSA-2 (80 mg/kg, orally) strongly affected epithelial cells with a significant decrease in the proportion of Hmga2+ and proliferating epithelial cells.
-
Mol Cell
2023 May 4;83(9):1502-1518.e10. PMID: 37086726 -
Nat Commun
Triple targeting of STING, TGF-β, and PD-L1 boosts CXCL16-CXCR6 signaling for potent antitumor response. [Abstract]2026 Feb 9;17(1):1441. PMID: 41663428 -
Nat Commun
Engineering STING Nanoadjuvants for spatiotemporally-tailored innate immunity stimulation and cancer vaccination therapy. [Abstract]2025 Jul 1;16(1):5773. PMID: 40595553 -
Cell Death Differ
Activating STING/TBK1 suppresses tumor growth via degrading HPV16/18 E7 oncoproteins in cervical cancer. [Abstract]2024 Jan;31(1):78-89. PMID: 38007552 -
Adv Sci (Weinh)
2024 Nov 19:e2407222. PMID: 39558862 -
Mater Today Bio
In situ administration of STING-activating hyaluronic acid conjugate primes anti-glioblastoma immune response. [Abstract]2024 Apr 16:26:101057. PMID: 38660475 -
BMC Med
TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro. [Abstract]2024 Mar 5;22(1):96. PMID: 38443977 -
Free Radic Biol Med
PGAM1-dependent VDAC1 oligomerization disrupts mitochondrial quality control to drive doxorubicin cardiotoxicity via the cGAS-STING-ferroptosis axis. [Abstract]2026 Apr:247:71-94. PMID: 41651300 -
ACS Appl Mater Interfaces
STING Agonist Delivered by Neutrophil Membrane-Coated Gold Nanoparticles Exerts Synergistic Tumor Inhibition with Radiotherapy. [Abstract]2024 Oct 9;16(40):53474-53488. PMID: 39316508 -
Free Radic Biol Med
Exogenous DNA enhances DUOX2 expression and function in human pancreatic cancer cells by activating the cGAS-STING signaling pathway. [Abstract]2023 Aug 20:205:262-274. PMID: 37330147 -
Oncogene
Targeting VPS4 elicits STING-driven anti-tumor immunity to suppress rhabdomyosarcoma growth. [Abstract]2026 Jun;45(23):2211-2224. PMID: 42032367 -
Oncogene
Synergistic reprogramming of the tumor immune microenvironment by Senecavirus A and STING agonist. [Abstract]2026 Mar;45(9):809-822. PMID: 41673092 -
J Med Chem
Discovery of a New Tetrahydroquinoline-Based Chemotype for STING Inhibition with In Vivo Efficacy against Acute Kidney Injury. [Abstract]2026 May 14;69(9):11044-11071. PMID: 41999331 -
Sci Signal
The APC/C adaptor Cdh1 stabilizes STING to potentiate innate immune activation in renal cell carcinoma. [Abstract]2026 Jun 23;19(943):eaef1474. PMID: 42335217 -
Oncoimmunology
The human STING agonist E7766 induces immunogenic tumor clearance, independent of tumor-intrinsic STING expression in the KRASG12D/+ Trp53-/- murine model of sarcoma. [Abstract]2025 Dec;14(1):2534912. PMID: 40693387 -
OncoImmunology
Stimulatory and inhibitory activity of STING ligands on tumor-reactive human gamma/delta T cells. [Abstract]2022 Feb 1;11(1):2030021. PMID: 35127253 -
PLoS Pathog
HIV-1 derived oligonucleotides induce a type I IFN/STING dependent immune suppression reversible by targeting IFNARI. [Abstract]2026 Jan 13;22(1):e1013868. PMID: 41529066 -
Int Immunopharmacol
Panobinostat suppresses cGAS-STING pathway activation and ameliorates DSS-induced colitis in mice. [Abstract]2025 Oct 10:167:115637. PMID: 41075748 -
Int Immunopharmacol
USP34 regulates PIN1-cGAS-STING axis-dependent ferroptosis in cervical cancer via SUMOylation. [Abstract]2025 Jan 2:147:113968. PMID: 39752760
MSA-2 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Jan 2:147:113968. [Abstract]
SN-011 (24, 48, or 72 h) reversed the reduction in cell proliferation caused by PIN1 knockdown in HeLa cells treated with sh-PIN1 or SiHa cells treated with pcDNA-PIN1 and MSA-2 (24, 48, or 72 h).
MSA-2 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Jan 2:147:113968. [Abstract]
Transwell assay demonstrated decreased migratory potential in sh-PIN1-treated HeLa cells, which was partially reversed by SN-011 (24 h) treatment. Conversely, MSA-2 (24 h) reduced the migration of pcDNA-PIN1-treated SiHa cells.
-
Cell Rep Methods
A fluorescent STING ligand sensor for high-throughput screening of compounds that can enhance tumor immunotherapy. [Abstract]2025 Jul 21;5(7):101106. PMID: 40669456 -
Sci Rep
Signal strength of STING activation determines cytokine plasticity and cell death in human monocytes. [Abstract]2022 Oct 24;12(1):17827. PMID: 36280676
MSA-2 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2022 Oct 24;12(1):17827. [Abstract]
Both diABZI (100 nM) and MSA-2 (25 µM) readily trigger the cleavage of caspase-3 and PARP-1 in monocytes. Low dose of MSA-2 (2.5 µM) and diABZI (100 nM) lead to the cleavage of gasdermin D (an indicator of pyroptosis) in monocytes.
-
Mol Divers
2025 Dec 11. PMID: 41379298 -
Bioorg Med Chem
2026 Jan 16:135:118571. PMID: 41564501 -
Cardiovasc Intervent Radiol
Injectable Multifunctional Hydrogel Consisted of Ultrasonic Marker and Immune Adjust Agent in Liver Tumor Ablation: Animal Experiment's Study. [Abstract]2025 Oct 31. PMID: 41174321 -
Chem Biodivers
Cyclopeptide Inhibitors Target the N-Terminal Tail of STING and Alleviate Autoinflammation. [Abstract]2024 Jul 12:e202401253. PMID: 38997793 -
Biomed Res
2026;47(3):89-101. PMID: 42178241 -
Cell Insight
2025 May 22;4(4):100255. PMID: 40586041 -
University of Rhode Island
-
Solvent & Solubility
DMSO : 50 mg/mL (169.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.07 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.07 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 25 mg/mL (84.94 mM); Suspended solution; Need ultrasonic
Add each solvent one by one: 1% CMC/saline water
Solubility: 5 mg/mL (16.99 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Pan BS, et al. An orally available non-nucleotide STING agonist with antitumor activity. Science. 2020;369(6506):eaba6098. [Content Brief]
[2]. Liu J, et al. Identification of MSA-2: An oral antitumor non-nucleotide STING agonist. Signal Transduct Target Ther. 2021;6(1):18. Published 2021 Jan 12. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3977 mL | 16.9883 mL | 33.9766 mL | 84.9416 mL |
| 5 mM | 0.6795 mL | 3.3977 mL | 6.7953 mL | 16.9883 mL | |
| 10 mM | 0.3398 mL | 1.6988 mL | 3.3977 mL | 8.4942 mL | |
| 15 mM | 0.2265 mL | 1.1326 mL | 2.2651 mL | 5.6628 mL | |
| 20 mM | 0.1699 mL | 0.8494 mL | 1.6988 mL | 4.2471 mL | |
| 25 mM | 0.1359 mL | 0.6795 mL | 1.3591 mL | 3.3977 mL | |
| 30 mM | 0.1133 mL | 0.5663 mL | 1.1326 mL | 2.8314 mL | |
| 40 mM | 0.0849 mL | 0.4247 mL | 0.8494 mL | 2.1235 mL | |
| 50 mM | 0.0680 mL | 0.3398 mL | 0.6795 mL | 1.6988 mL | |
| 60 mM | 0.0566 mL | 0.2831 mL | 0.5663 mL | 1.4157 mL | |
| 80 mM | 0.0425 mL | 0.2124 mL | 0.4247 mL | 1.0618 mL | |
| 100 mM | 0.0340 mL | 0.1699 mL | 0.3398 mL | 0.8494 mL |